drugset / Trial / NCT00445484

Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00445484

RandomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Vaccines may help the body build an effective immune response to kill cancer cells. Giving lenalidomide together with vaccine therapy may make a stronger immune response and kill more cancer cells. PURPOSE: This phase II trial is studying how well giving lenalidomide together with vaccine therapy works in treating patients with relapsed or refractory multiple myeloma.

Timeline

Start
2007-01
Primary completion
2009-04
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenalidomide Other / unclassified Oral
Subject Pneumovax 23 Vaccine Intramuscular

Indications